FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Paget's Disease

Actonel (by Procter & Gamble, Hoechst Marion Roussel), Approved April 1998
Treatment for Paget's Disease

Fosamax (alendronate sodium) (by Merck), Approved on September 29, 1995
Treatment for osteoporosis in women after menopause and Paget's Disease of Bone

Reclast (zoledronic acid) (by Novartis), Approved April 2007
For the treatment of Paget's disease

Skelid (tiludronate disodium) (by Sanofi-aventis), Approved March 1997
Treatment for Paget’s disease of bone

Pain

Belbuca (buprenorphine) (by Endo Pharmaceuticals), Approved October 2015
For the management of severe pain

Bromfenac (by Duract, Wyeth-Ayerst Laboratories), Approved July 1997
Management of acute pain

Dyloject (diclofenac sodium) Injection (by Hospira), Approved December 2014
For the management of mild, moderate or severe pain

Embeda (morphine sulfate and naltrexone hydrochloride) (by King Pharmaceuticals), Approved August of 2009
For the treatment of moderate to severe pain

Exalgo (hydromorphone hydrochloride) extended release (by Alza), Approved March 2010
For the management of moderate to severe pain

Exparel (bupivacaine liposome injectable suspension) (by Pacira Pharmaceuticals), Approved November 2011
For postsurgical analgesia

NORCO tablets (Hydrocodone Bitartrate/Acetaminophen 10 mg/325 mg) (by Watson Pharmaceuticals), Approved February 1997
Treatment for moderate to moderately severe pain

Oxecta (oxycodone HCl) (by Pfizer), Approved June 2011
For the management of acute and chronic moderate to severe pain

OxyContin (oxycodone HCl controlled-release) (by Purdue Pharma), Approved May 1996
Treatment for pain associated with musculoskeletal conditions

Sprix (ketorolac tromethamine) (by Roxro Pharma), Approved May 2010
For the treatment of moderate to severe pain

Subsys (fentanyl sublingual spray) (by Insys Therapeutics), Approved January of 2012
For the treatment of breakthrough cancer pain

Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets (by Purdue Pharma), Approved July 2014
For the management of severe chronic pain

Tivorbex (indomethacin) (by Iroko Pharmaceuticals), Approved February of 2014
For the treatment of acute pain

Ultracet (acetaminophen and tramadol HCl) (by Ortho-McNeil Pharmaceutical), Approved August 2001
For the short-term management of acute pain

Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release (by Mallinckrodt Pharmaceuticals), Approved March 2014
For the management of acute pain

Zipsor (diclofenac potassium) (by Xanodyne Pharmaceuticals), Approved June 2009
For the treatment of mild to moderate acute pain

Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules (by Zogenix), Approved October 2013
For the management of severe pain

Pain; Bone Neoplasms; Neoplasm Metastasis

Subsys (fentanyl sublingual spray) (by Insys Therapeutics), Approved January of 2012
For the treatment of breakthrough cancer pain

Pancreatic Cancer

Gemzar (gemcitabine HCL) (by Eli Lilly), Approved May 1996
Treatment for pancreatic cancer

Onivyde (irinotecan liposome injection) (by Merrimack), Approved October 2015
For the treatment of metastatic pancreatic cancer following gemcitabine-based therapy

Pancreatic Disorders

Pancreaze (pancrelipase) (by Johnson & Johnson), Approved April of 2010
For the treatment of exocrine pancreatic insufficiency

SecreFlo (secretin) (by Repligen), Approved April 2002
To aid in the diagnosis of pancreatic dysfunction and gastrinoma

Ultresa (pancrelipase) delayed-release capsules (by Aptalis Pharma), Approved March 2012
For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Viokace (pancrelipase) tablets (by Aptalis Pharma), Approved March 2012
For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy

Zenpep (pancrelipase) (by Eurand), Approved August 2009
For the treatment of pancreatic insufficiency due to cystic fibrosis or other conditions

Pancreatitis

Viokace (pancrelipase) tablets (by Aptalis Pharma), Approved March 2012
For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy

Panic Disorders

Paxil (paroxetine hydrochloride) (by SmithKline Beecham), Approved May 1996
Treatment for panic disorder

Paxil CR (paroxetine hydrochloride) (by GlaxoSmithKline), Approved February 2002
Oral tablet for the treatment of depression and panic disorder

Zoloft (sertraline HCl) (by Pfizer), Approved July 1997
Treatment for panic disorder

Zoloft (sertraline HCl) (by Pfizer), Approved October 1997
Treatment of panic disorder in children ages 6-17

Parathyroid Disorders

Parsabiv (etelcalcetide) (by Amgen), Approved February 2017
For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis

Rayaldee (calcifediol) (by Opko Health), Approved June 2016
For the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease

Parkinson's Disease

Apokyn (apomorphine hydrochloride) (by Mylan Laboratories), Approved April, 2004
For the treatment of acute, intermittent hypomobility episodes associated with advanced Parkinson’s disease

Comtan (by Novartis), October 19, 1999
200mg entacapone tablets

Duopa (carbidopa and levodopa) enteral suspension (by Abbvie), Approved January 2015
For the treatment of motor fluctuations in patients with advanced Parkinson's disease

Exelon (rivastigmine tartrate) (by Novartis), Approved July 2007
For the treatment of Alzheimer's and Parkinson's disease-related dementia

Gocovri (amantadine) (by Adamas Pharmaceuticals), Approved August 2017
For the treatment of Parkinson's disease dyskinesia

Mirapex (by Pharmacia & Upjohn, Boehringer Ingelheim), Approved June 1997
Treatment for Parkinson’s Disease

Neupro (rotigotine) (by Schwarz Pharma), Approved May 2007
For the treatment of Parkinson's disease

Nuplazid (pimavanserin) (by Acadia Pharmaceuticals), Approved April 2016
For the treatment of hallucinations and delusions associated with Parkinson’s disease

Nuplazid (pimavanserin) (by Acadia Pharmaceuticals), Approved May 2016
For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis

Pramipexole (by Pharmacia & Upjohn), Approved July 1997
Treatment for Parkinson's Disease

Requip (ropinirole hydrochloride) (by SmithKline Beecham), Approved September 1997
Treatment for Parkinson's Disease

Rytary (carbidopa and levodopa) extended-release capsules (by Impax Labs), Approved January 2015
For the treatment of Parkinson's disease

Selegiline tablets (by Teva Pharmaceutical), Approved January 1997
Generic equivalent of Eldepryl tablets

Tasmar (by Roche), Approved January 1998
Treatment for Parkinson's Disease

Xadago (safinamide) (by Newron Pharmaceuticals), Approved March 2017
For the treatment of Parkinson's disease

Pediatric Health

Actemra (ocilizumab) (by Genentech), Approved May 2013
For the treatment of Polyarticular Juvenile Idiopathic Arthritis

Benznidazole (by Chemo Group), Approved August 2017
For the treatment of Chagas disease

Bexsero (Meningococcal Group B Vaccine) (by Novartis), Approved January 2015
For the treatment of invasive meningococcal disease caused by serogroup B

Brineura (cerliponase alfa) (by BioMarin), Approved April 2017
For the treatment of late infantile neuronal ceroid lipofuscinosis type 2

Cuvposa (glycopyrrolate) (by Shionogi), Approved July 2010
For the treatment of chronic severe drooling in pediatrics with neurologic conditions

Emflaza (deflazacort) (by Marathon Pharmaceuticals), Approved February 2017
For the treatment of Duchenne muscular dystrophy

Kineret, anakinra (by Swedish Orphan Biovitrum), Approved January 2013
For the treatment of Cryopyrin-Associated Periodic Syndromes

Kovaltry [Antihemophilic Factor (Recombinant)] (by Bayer ), Approved March 2016
For the treatment of hemophillia A

Kynamro (mipomersen sodium) (by Genzyme), Approved January 2013
For the treatment of homozygous familial hypercholesterolemia

Orkambi (lumacaftor and ivacaftor) (by Vertex Pharmaceuticals), Approved July 2015
For the treatment of cystic fibrosis

Quillivant XR (methylphenidate hydrochloride) (by NextWave Pharmaceuticals), Approved September 2012
For the treatment of Attention Deficit Hyperactivity Disorder

Soliris (eculizumab) (by Alexion), Approved March 2007
For the treatment of PNH, aHUS and generalized Myasthenia Gravis

Surfaxin (lucinactant) (by Discovery Laboratories), Approved March 2012
For the treatment of respiratory distress syndrome in premature infants

Unituxin (dinutuximab) (by United Therapeutics), Approved March 2015
For the treatment of pediatrics with high-risk neuroblastoma

Vimizim (elosulfase alfa) (by BioMarin), Approved February 2014
For the treatment of Mucopolysaccharidosis type IVA

Periodontitis

Atridox (by Atrix Laboratories), Approved September 1998
Treatment for periodontal disease

Peripheral Arterial Disease (PAD)

Zontivity (vorapaxar) (by Merck), Approved May 2014
For the reduction of thrombotic cardiovascular events

Peripheral Arterial Occlusive Disease

Pentoxifylline (by Faulding, Mylan Laboratories), Approved July 1997
Generic equivalent of Trental

Peritoneal Cancer

Zejula (niraparib) (by Tesaro), Approved March 2017
For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Peyronie's Disease

Xiaflex (collagenase clostridium histolyticum) (by Auxilium), Approved December of 2013
For the treatment of Peyronie's disease

Xiaflex (collagenase clostridium histolyticum) (by Auxilium Pharmaceuticals), Approved February 2010
For the treatment of Dupuytren’s contracture

Pneumonia

Augmentin (amoxicillin/clavulanate) (by SmithKline Beecham), Approved February 1996
Treatment for infections involving drug-resistant bacteria

Avelox I.V. (moxifloxacin hydrochloride) (by Bayer), Approved November 2001
Injectable antibacterial agent for adults with susceptible strains of bacterial infections

Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) (by Wyeth), Approved February 2010
For the active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae

Vibativ (telavancin) (by Theravance), Approved June 2013
For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus

Vibativ (telavancin) (by Theravance), Approved September 2009
For the treatment of complicated skin and skin structure infections

Zagam (sparfloxacin) tablets (by Rhone Poulenc Rorer), Approved January 1997
Treatment for community-acquired pneumonia (CAP) and chronic bronchitis

Zosyn (sterile piperacillin sodium/tazobactam sodium) (by Wyeth), Approved May 1996
Treatment for hospital-acquired pneumonia

Post Menopause

Arimidex (anastrozole) (by AstraZeneca), Approved January 1996
Treatment for advanced breast cancer in postmenopausal women

Posterior Uveitis

Humira (adalimumab) (by Abbvie), Approved July 2016
For the treatment of uveitis

Postherpetic Neuralgia

Horizant (gabapentin enacarbil) (by GlaxoSmithKline), Approved April 2011
For the treatment of restless legs syndrome

Horizant (gabapentin enacarbil) (by GlaxoSmithKline), Approved June 2012
For the treatment of postherpetic neuralgia

Post-Menopausal Osteoporosis

Alora (by Watson Pharmaceuticals), Approved April 2002
Transdermal patch for the prevention of postmenopausal osteoporosis and treatment of vasomotor menopausal symptoms

Estradiol tablets (by Barr Laboratories), Approved October 1997
Generic equivalent of Estrace

Evista (raloxifene hydrochloride) (by Eli Lilly), Approved September 1999
Osteoporosis treatment

Evista (raloxifene hydrochloride) (by Eli Lilly), Approved September 2007
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women

Fosamax (alendronate sodium) (by Merck), Approved on September 29, 1995
Treatment for osteoporosis in women after menopause and Paget's Disease of Bone

Miacalcin (calcitonin-salmon) Nasal Spray (by Sandoz Pharmaceuticals), Approved on August 17, 1995
Treatment for post-menopausal osteoporosis

Premarin (conjugated estrogens) (by Wyeth), Approved July of 2003
For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms

Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets) (by Wyeth), Approved November 1995
Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis

Prolia (denosumab) (by Amgen), Approved June 2010
For the treatment of postmenopausal women with osteoporosis at high risk for fracture

Reclast (zoledronic acid) (by Novartis), Approved August 2007
For the treatment of postmenopausal osteoporosis

Tymlos (abaloparatide) (by Radius Health), Approved April 2017
For the treatment of postmenopausal women with osteoporosis at high risk for fracture

Post-Surgical Pain

Exparel (bupivacaine liposome injectable suspension) (by Pacira Pharmaceuticals), Approved November 2011
For postsurgical analgesia

Precancerous condition

Picato (ingenol mebutate) gel (by LEO Pharma), Approved January 2012
For the treatment of actinic keratosis

Pregnancy

Diclegis (doxylamine succinate + pyridoxine hydrochloride DR tablets) (by Duchesnay USA), Approved April 2013
For the treatment of nausea and vomiting of pregnancy

Lo Minastrin, (norethindrone acetate, ethinyl estradiol, ferrous fumarate) (by Warner Chilcott), Approved July 2013
For the prevention of pregnancy

Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) (by Teva Pharmaceutical), Approved April 2013
For the prevention of conception

Pregnancy Complications

Diclegis (doxylamine succinate + pyridoxine hydrochloride DR tablets) (by Duchesnay USA), Approved April 2013
For the treatment of nausea and vomiting of pregnancy

Makena (hydroxyprogesterone caproate injection) (by Hologic), Approved February 2011
For the prevention of risk of preterm birth

Primary Immunodeficiency Disorders

HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] (by Baxter), Approved September 2014
For the treatment of Primary Immunodeficiency

Prostate Cancer

Degarelix (degarelix for injection) (by Ferring Pharmaceuticals), Approved December of 2008
For the treatment of prostate cancer

Eligard (leuprolide acetate) (by Atrix Laboratories), Approved January 2002
For the palliative treatment of advanced prostate cancer

Eulexin (flutamide) (by Schering-Plough), Approved June 1996
Treatment for prostate cancer

Jevtana (cabazitaxel) (by sanofi aventis), Approved June 2010
For the treatment of prostate cancer

Lupron Depot (leuprolide acetate for depot suspension) (by Abbott Laboratories), Approved January 1996
Treatment for advanced prostate cancer

Lupron Depot (leuprolide acetate for depot suspension) (by TAP Pharmaceuticals), Approved July 1997
Treatment for prostate cancer

Plenaxis (abarelix for injectable suspension) (by Praecis Pharmaceuticals), Approved December 2003
For treatment of advanced prostate cancer

Provenge (sipuleucel-T) (by Dendreon), Approved May 2010
For the treatment of hormone refractory prostate cancer

Trelstar Depot (triptorelin pamoate) (by Debio Rechereche Pharmaceutique, Target Research Associates), Approved June 2000
For the palliative treatment of advanced prostate cancer

Trelstar LA (triptorelin pamoate) (by Debiopharm), Approved June 2001
Intramuscular injection for the treatment of advanced stage prostate cancer

Viadur (leuprolide acetate implant) (by Alza), Approved March 2000
For pain relief in men with advanced prostate cancer

Xofigo (radium Ra 223 dichloride) (by Bayer Healthcare Pharmaceuticals), Approved May 2013
For the treatment of prostate cancer with bone metastases

Xtandi (enzalutamide) (by Medivation), Approved August 2012
For the treatment of metastatic castration-resistant prostate cancer

Zoladex (10.8 mg goserelin acetate implant) (by AstraZeneca), Approved January 1996
Treatment for advanced prostate cancer

Zytiga (abiraterone acetate) (by Centocor Ortho Biotech), Approved May 2011
For the treatment of prostate cancer

Pseudobulbar Affect

Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) (by Avanir Pharmaceuticals), Approved October 2010
For the treatment of pseudobulbar affect

Psoriasis and Psoriatic Disorders

Amevive (alefacept) (by Biogen IDEC), Approved January 2003
For moderate to severe chronic plaque psoriasis.

Cosentyx (secukinumab) (by Novartis), Approved January 2015
For the treatment of plaque psoriasis

Enstilar (calcipotriene and betamethasone dipropionate) (by LEO Pharmaceuticals), Approved October 2015
For the treatment of psoriasis

Otezla (apremilast) (by Celgene), Approved September 2014
For the treatment of moderate to severe plaque psoriasis

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Siliq (brodalumab) (by Valeant Pharmaceuticals), Approved February 2017
For the treatment of plaque psoriasis

Stelara (ustekinumab) (by Janssen Biotech), Approved September 2009
For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease

Taltz (ixekizumab) (by Eli Lilly), Approved March 2016
For the treatment of plaque psoriasis and active psoriatic arthritis

Tazorac topical gel (by Allergan), Approved June 1997
Treatment for Psoriasis, Acne Vulgaris

Tremfya (guselkumab) (by Janssen Biotech), Approved July 2017
For the treatment of moderate-to-severe plaque psoriasis

Psoriatic Arthritis

Enbrel (etanercept) (by Immunex), Approved January 2002
For the treatment of psoriatic arthritis

Otezla (apremilast) (by Celgene), Approved March 2014
For the treatment of adults with active psoriatic arthritis

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Stelara (ustekinumab) (by Janssen Biotech), Approved September 2009
For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease

Taltz (ixekizumab) (by Eli Lilly), Approved March 2016
For the treatment of plaque psoriasis and active psoriatic arthritis

Psychosis

Nuplazid (pimavanserin) (by Acadia Pharmaceuticals), Approved May 2016
For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis

Prochlorperazine (by IVAX), Approved January 1998
Generic equivalent of SmithKline Beecham's Compazine

Seroquel (R) (quetiapine fumarate) Tablets (by AstraZeneca), Approved September 1997
Treatment for schizophrenia

Zyprexa (by Eli Lilly), Approved September 1996
Treatment of the symptoms of psychotic disorders

Pulmonary Arterial Hypertension

Adcirca (tadalafil) (by Eli Lilly), Approved May 2009
For the treatment of pulmonary arterial hypertension

Adempas (riociguat) (by Bayer Healthcare Pharmaceuticals), Approved October 2013
For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension

Letairis (ambrisentan) (by Gilead), Approved June 2007
For the treatment of pulmonary arterial hypertension

Opsumit (macitentan) (by Actelion Pharmaceuticals), Approved October 2013
For the treatment of pulmonary arterial hypertension

Remodulin (treprostinil) (by United Therapeutics), Approved May 2002
For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms

Tracleer (bosentan) (by Actelion), Approved November 2001
For the treatment of pulmonary arterial hypertension

Tyvaso (treprostinil) (by United Therapeutics), Approved July 2009
For the treatment of pulmonary arterial hypertension

Uptravi (selexipag) (by Actelion Pharmaceuticals), Approved December 2015
For the treatment of pulmonary arterial hypertension

Pulmonary Embolism

Savaysa (edoxaban) (by Daiichi Sankyo), Approved January 2015
For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation